FIELD: medicine.
SUBSTANCE: invention relates to use of histone deacetylase inhibitors in treatment of degenerative eye diseases.
EFFECT: therapeutic effect is conditioned by protective activity of histone deacetylase inhibitors in relation to retinal ganglionic cells under cytotoxic exposure.
6 ex, 4 cl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF HISTONDEACETYLASE FOR TREATMENT OF OPHTHALMOLOGIC NEOVASCULAR DISTURBANCES AND DISEASES | 2003 |
|
RU2352337C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| NEUTRAL ENDOPEPTIDASE (NEP) AND SOLUBLE HUMAN ENDOPEPTIDASE (SHE) INHIBITORS FOR PREVENTION AND TREATMENT OF EYE DISEASES | 2019 |
|
RU2758771C1 |
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| BDNF-BASED (BRAIN-DERIVED NEUROTROPHIC FACTOR) OPHTHALMIC PREPARATIONS AND USING THEM | 2010 |
|
RU2564920C2 |
| COMPOSITIONS AND METHODS OF SPHINGOSINE-1-PHOSPHATE BINDING | 2007 |
|
RU2460541C2 |
| METHOD FOR IMPROVING FUNCTIONAL RETINA ACTIVITY IN THE CASES OF ITS ABNORMALITY OF VARIOUS GENESIS | 2004 |
|
RU2279886C2 |
| USE OF SUBSTANCES FOR TREATING VISION LOSS IN INDIVIDUALS SUFFERING GLAUCOMA AND OTHER DEGENERATIVE OCULAR DISEASES | 2008 |
|
RU2481120C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| METHOD OF DETERMINING INDICATIONS FOR TREATMENT OF OPHTHALMOLOGICAL COMPLICATIONS OF SYSTEMIC ATHEROSCLEROSIS | 2012 |
|
RU2494679C1 |
